Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rami Kahwash

Advanced Heart Failure and Transplant Cardiology Columbus, OH Medical Doctor

NPI 1053515718 CMS profile 450422

181 Taylor Ave Fl 13, Columbus, OH 43203

Open in the dashboard

General payments

$378,563

256 records reported · program years 2019–2025

Research payments

$119,571

Paid to them · 62 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$595,183 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Rami Kahwash of Columbus, OH is reported in the CMS Open Payments database as having received $378,563 across 256 general payments and $119,571 in research payments paid to them. Separately, studies naming them as principal investigator received $595,183 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $77,038 60
2025 Research $16,638 8
2024 General $58,887 42
2024 Research $28,000 13
2023 General $93,130 68
2023 Research $26,849 23
2022 General $71,109 44
2022 Research $14,963 6
2021 General $45,692 20
2021 Research $12,825 4
2020 General $27,750 2
2020 Research $15,548 6
2019 General $4,957 20
2019 Research $4,750 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rami Kahwash
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Rami Kahwash were reported at $77,038. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Rami Kahwash Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $4,957 $863 $224–$4,562 $163
2020 $27,750 $452 $122–$3,992 $114
2021 $45,692 $550 $159–$3,571 $132
2022 $71,109 $729 $221–$4,357 $149
2023 $93,130 $1,002 $309–$5,827 $160
2024 $58,887 $931 $273–$5,204 $164
2025 $77,038 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Impulse Dynamics (USA) Inc. $320,002 174 payments
  2. Edwards Lifesciences Corporation $29,726 16 payments
  3. Medtronic, Inc. $11,140 31 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $7,714 7 payments
  5. Medtronic Vascular, Inc. $5,707 21 payments
  6. Scpharmaceuticals Inc. $4,000 2 payments
  7. AstraZeneca Pharmaceuticals LP $135 2 payments
  8. BridgeBio Pharma, Inc. $100 1 payment
  9. Abiomed $24 1 payment
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $204,310 47 payments
  2. Honoraria $142,950 48 payments
  3. Travel and Lodging $24,038 62 payments
  4. Food and Beverage $7,251 98 payments
  5. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. OPTIMIZER Cardiovascular Device $181,227 120 payments
  2. OPTIMIZER Cardiovascular Device $181,227 120 payments
  3. Optimizer Cardiovascular $70,283 36 payments
  4. Optimizer Cardiovascular $59,689 24 payments
  5. Optimizer Smart System Cardiovascular Device $41,492 17 payments
  6. OPTIMIZER SMART SYSTEM Cardiovascular Device $27,000 1 payment
  7. Kerendia $7,714 7 payments
  8. FUROSCIX $4,000 2 payments
  9. Reveal LINQ Cardiac Diagnostics and Monitoring $2,047 22 payments
  10. Reveal LINQ Cardiac Diagnostics and Monitoring $597 6 payments
  11. Other $568 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $99,274 54 payments
  2. Medtronic Vascular, Inc. $20,298 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,648

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$1,984,833

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

32%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 37 $1,078,000
Entresto Sacubitril/Valsartan Brand 299 $381,904
Farxiga Dapagliflozin Propanediol Brand 163 $176,274
Jardiance Empagliflozin Brand 141 $168,407
Eliquis Apixaban Brand 101 $122,509
Xarelto Rivaroxaban Brand 21 $17,274
Mycophenolate Mofetil Generic 83 $7,158
Eplerenone Generic 76 $6,286
Tacrolimus Generic 79 $5,078
Sirolimus Generic 14 $3,931

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$71,155

Medicare's payments for the services billed

Medicare patients

248

Average age 71

Services billed

763

89 women, 159 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 60%
Atrial fibrillation 59%
Chronic kidney disease 58%
Diabetes 48%
Arthritis 46%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $121
$121 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

318 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record